文献速递产科母胎医学

阿司匹林用于循证子痫前期预防试验:阿司匹林对妊娠期母体血清妊娠相关血浆蛋白A和胎盘生长因子轨迹的影响

Aspirin for evidence-based preeclampsia prevention trial: effects of aspirin on maternal serum pregnancy-associated plasma protein A and placental growth factor trajectories in pregnancy.
PubMed 文献 · Am J Obstet Gynecol · 2023-12-25

该研究为阿司匹林预防子痫前期试验的纵向二次分析,纳入1620例子痫前期高危孕妇,798例随机接受阿司匹林150 mg每日,822例接受安慰剂。结果显示,阿司匹林组与安慰剂组的妊娠相关血浆蛋白A和胎盘生长因子中位数倍数轨迹无显著差异(交互作用P值分别为.259和.335)。

要点

  • 阿司匹林150 mg每日对早产子痫前期高危孕妇的妊娠相关血浆蛋白A轨迹无显著影响(交互作用P=.259)。
  • 阿司匹林150 mg每日对胎盘生长因子轨迹无显著影响(交互作用P=.335)。
  • 研究人群的妊娠相关血浆蛋白A和胎盘生长因子中位数倍数均值持续低于1.0,反映高危特征。

核心结论

  • 在早产子痫前期高危孕妇中,与安慰剂相比,阿司匹林150 mg每日对妊娠相关血浆蛋白A或胎盘生长因子轨迹无显著影响。

研究设计与样本

  • 该研究为阿司匹林用于循证子痫前期预防试验的纵向二次分析,使用妊娠相关血浆蛋白A和胎盘生长因子的重复测量数据。
  • 试验中,1620例早产子痫前期高危孕妇在孕11至13+6周通过胎儿医学基金会算法识别,798例随机接受阿司匹林150 mg每日,822例接受安慰剂每日,从孕14周前至孕36周。
  • 血清生物标志物在基线以及孕19至24周、32至34周和36周的随访访视时测量。
  • 采用广义加性混合模型,含治疗与孕周交互项,分析阿司匹林对生物标志物轨迹的影响。

主要发现

  • 总体共有5507次妊娠相关血浆蛋白A测量和5523次胎盘生长因子测量。
  • 原始妊娠相关血浆蛋白A值随时间增加,原始胎盘生长因子增至孕32周后下降。
  • 同一生物标志物的中位数倍数均值持续低于1.0中位数倍数,反映研究人群的高危特征。
  • 妊娠相关血浆蛋白A和胎盘生长因子中位数倍数均值的轨迹在阿司匹林组与安慰剂组间无显著差异(阿司匹林治疗与孕周交互作用P值分别为.259和.335)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The exact mechanism by which aspirin prevents preeclampsia remains unclear. Its effects on serum placental biomarkers throughout pregnancy are also unknown. OBJECTIVE: To investigate the effects of aspirin on serum pregnancy-associated plasma protein A and placental growth factor trajectories using repeated measures from women at increased risk of preterm preeclampsia. STUDY DESIGN: This was a longitudinal secondary analysis of the Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-based Preeclampsia Prevention trial using repeated measures of pregnancy-associated plasma protein A and placental growth factor. In the trial, 1620 women at increased risk of preterm preeclampsia were identified using the Fetal Medicine Foundation algorithm at 11 to 13+6 weeks of gestation, of whom 798 were randomly assigned to receive aspirin 150 mg and 822 to receive placebo daily from before 14 weeks to 36 weeks of gestation. Serum biomarkers were measured at baseline and follow-up visits at 19 to 24, 32 to 34, and 36 weeks of gestation. Generalized additive mixed models with treatment by gestational age interaction terms were used to investigate the effect of aspirin on biomarker trajectories over time. RESULTS: Overall, there were 5507 pregnancy-associated plasma protein A and 5523 placental growth factor measurements. Raw pregnancy-associated plasma protein A values increased over time, and raw placental growth factor increased until 32 weeks of gestation followed by a decline. The multiple of the median mean values of the same biomarkers were consistently below 1.0 multiple of the median, reflecting the high-risk profile of the study population. Trajectories of mean pregnancy-associated plasma protein A and placental growth factor multiple of the median values did not differ significantly between the aspirin and placebo groups (aspirin treatment by gestational age interaction P values: .259 and .335, respectively). CONCLUSION: In women at increased risk of preterm preeclampsia, aspirin 150 mg daily had no significant effects on pregnancy-associated plasma protein A or placental growth factor trajectories when compared to placebo.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Rolnik DL, Syngelaki A, O'Gorman N, et al. Aspirin for evidence-based preeclampsia prevention trial: effects of aspirin on maternal serum pregnancy-associated plasma protein A and placental growth factor trajectories in pregnancy. Am J Obstet Gynecol. 2023. PMID: 38151219. doi:10.1016/j.ajog.2023.12.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。